

Royalty Pharma plc (RPRX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001802768

Royalty Pharma plc	
RPRX; healthcare	
Grade	D fourth fifth of 371 graded peers percentile 63.8; sampling error 2.5 points; lower is stronger
Rank	237 of 371
Profitability	C percentile 47.3
Solvency	C/D percentile 59.0
Growth and financing	C percentile 53.2
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$19.6B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: dilution, distress
Inputs computable	7 of 14
Graded from	filings received through Feb 11, 2026 240 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	\$56.22 2026-10-08; market equity \$21.8B
Price used in grade	None

D, the sloth
fourth fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan
split-adjusted close; the letter is fixed at the rescan that set it

Rescans on file: B from Feb 21, 2024, C/D from Feb 21, 2026, D from Mar 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 11, 2026

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 47.3						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		8.9%	9.3%	50.7	74	2025-12-31
Accruals ratio		(9.1%)	(6.6%)	44.0	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 59.0						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		2.25	(0.31)	27.8	756	2025-12-31
Net debt to EBITDA		5.33x	1.82x	83.8	75	2025-12-31
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		2.40x	2.96x	65.3	839	2025-12-31
Growth and financing, sleeve percentile 53.2						
Revenue growth, three-year compound		2.1%	10.0%	66.4	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 0
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		5.3%	2.1%	40.0	704	2025-12-31
Net share issuance, one year		not computable	2.5%			two annual share counts are required; found 0

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
232	Embecta Corp. (EMBC)	62.4	C/D	late filer
233	Biogen Inc. (BIIB)	62.7	D	
234	Lenz Therapeutics, Inc. (LENZ)	63.0	D	short runway
235	AbbVie Inc. (ABBV)	63.2	D	
236	Caribou Biosciences, Inc. (CRBU)	63.5	D	short runway
237	Royalty Pharma plc (RPRX) <	63.8	D	
238	Integra Lifesciences Holdings Corp. (IART)	64.1	D	
239	Alpha Teknova, Inc. (TKNO)	64.3	D	
240	Arvinas, Inc. (ARVN)	64.6	D	short runway, fortress balance sheet
241	Organogenesis Holdings Inc. (ORGO)	64.9	D	fortress balance sheet
242	Fulgent Genetics, Inc. (FLGT)	65.1	D	short runway

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	77.4%	8.0%	84
Distance from 52-week high	(12.1%)	(31.4%)	80
EBIT to enterprise value	5.2%	(1.5%)	80
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.45	0.28	67
Sales to price	0.11	0.31	26
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	0.36	(0.14)	84

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$812.0M
Operating cash flow, four quarters	\$3.0B
Months of runway	not finite

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	\$1.6B	2025-12-31	2026-02-11	10-K	0001802768-26-000003
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$1.3B	2025-12-31	2026-02-11	10-K	0001802768-26-000003
3	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2025-12-31	2026-02-11	10-K	0001802768-26-000003
4	total debt	us-gaap:LongTermDebt	\$9.0B	2025-12-31	2026-02-11	10-K	0001802768-26-000003
5	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingIn	\$9.3B	2025-12-31	2026-02-11	10-K	0001802768-26-000003
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$618.7M	2025-12-31	2026-02-11	10-K	0001802768-26-000003
7	total debt	us-gaap:LongTermDebt	\$7.6B	2024-12-31	2026-02-11	10-K	0001802768-26-000003
8	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingIn	\$9.3B	2024-12-31	2026-02-11	10-K	0001802768-26-000003
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$929.0M	2024-12-31	2026-02-11	10-K	0001802768-26-000003
10	net income	us-gaap:NetIncomeLoss	\$770.9M	2025-12-31	2026-02-11	10-K	0001802768-26-000003
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.5B	2025-12-31	2026-02-11	10-K	0001802768-26-000003
12	assets	us-gaap:Assets	\$19.6B	2025-12-31	2026-02-11	10-K	0001802768-26-000003
13	assets	us-gaap:Assets	\$18.2B	2024-12-31	2026-02-11	10-K	0001802768-26-000003
14	current assets	us-gaap:AssetsCurrent	\$1.5B	2025-12-31	2026-02-11	10-K	0001802768-26-000003
15	current liabilities	us-gaap:LiabilitiesCurrent	\$636.2M	2025-12-31	2026-02-11	10-K	0001802768-26-000003
16	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$2.4B	2025-12-31	2026-02-11	10-K	0001802768-26-000003
17	liabilities	us-gaap:Liabilities	\$9.9B	2025-12-31	2026-02-11	10-K	0001802768-26-000003
18	depreciation amortization	us-gaap:Depreciation	\$3.9M	2025-12-31	2026-02-11	10-K	0001802768-26-000003
19	operating income	us-gaap:OperatingIncomeLoss	\$1.5B	2023-12-31	2026-02-11	10-K	0001802768-26-000003
20	interest expense	us-gaap:InterestExpense	\$187.2M	2023-12-31	2024-02-15	10-K	0001802768-24-000012
21	revenue	us-gaap:Revenues	\$2.4B	2025-12-31	2026-02-11	10-K	0001802768-26-000003
22	revenue	us-gaap:Revenues	\$2.3B	2024-12-31	2026-02-11	10-K	0001802768-26-000003
23	revenue	us-gaap:Revenues	\$2.4B	2023-12-31	2026-02-11	10-K	0001802768-26-000003
24	revenue	us-gaap:Revenues	\$2.2B	2022-12-31	2025-02-12	10-K	0001802768-25-000010
25	assets	us-gaap:Assets	\$16.4B	2023-12-31	2025-02-12	10-K	0001802768-25-000010
26	assets	us-gaap:Assets	\$16.8B	2022-12-31	2024-02-15	10-K	0001802768-24-000012